LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

Revvity to Present at Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$96.77 0.50 0.52

WALTHAM, Mass. / Aug 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in September 2024:

2024 Wells Fargo Healthcare Conference – Boston, MA

Wednesday, September 4, 2024
8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

2024 Baird Global Healthcare Conference – New York City, NY

Tuesday, September 10, 2024
12:15 p.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk

Attendees will receive an update on the Company and its strategic priorities.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page